Study guide
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity
Key Takeaways Explain This Topic AI
Acute digoxin toxicity presents primarily with gastrointestinal distress, life-threatening dysrhythmias, and severe hyperkalemia reflecting systemic Na+/K+ ATPase pump inhibition; chronic toxicity manifests insidiously with visual disturbances, delirium, bradycardia, and normal or low serum potassium.
Digoxin-specific antibody fragments (DigiFab) are indicated for life-threatening dysrhythmias, serum potassium >5.0 mEq/L in acute overdose, acute ingestions >10 mg in adults (>4 mg in children), or serum digoxin >10 to 15 ng/mL; empiric dosing is 10 to 20 vials for unknown acute ingestions and 3 to 6 vials for chronic toxicity.
Post-DigiFab serum digoxin assays become falsely elevated and clinically uninterpretable because commercial immunoassay kits quantify both pharmacologically active free drug and inactive antibody-bound drug.
Tricyclic antidepressant (TCA) toxicity causes myocardial fast sodium channel blockade where QRS >100 ms predicts seizures and QRS >160 ms predicts ventricular dysrhythmias; treatment requires intravenous sodium bicarbonate (1-2 mEq/kg boluses and continuous infusion) to narrow QRS and maintain arterial pH between 7.45 and 7.55.
Physostigmine (0.5-2 mg slow IV over 5 minutes) is a tertiary amine acetylcholinesterase inhibitor that crosses the blood-brain barrier to reverse anticholinergic delirium, but it is strictly contraindicated in TCA overdose, QRS widening >100 ms, PR prolongation, and asthma due to risk of fatal asystole.
Last updated: October 2026
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity
Note
Independent BCEMP study resource provided by ExamFinch. Content covers emergency toxicology, specialized antidotes, and clinical pharmacotherapy principles.
Cardiovascular and central nervous system (CNS) toxins account for some of the most critical resuscitations encountered by emergency medicine pharmacists. Digoxin, tricyclic antidepressants (TCAs), and antimuscarinic agents each present distinct toxicologic profiles with overlapping features—such as conduction delays, dysrhythmias, and altered mental status—yet their antidote indications, cellular targets, and pharmacotherapeutic rescue strategies diverge significantly. Mastery of these specialized poisonings requires immediate recognition of electrophysiologic hallmarks, precise dosing calculations under physiological crisis, and rigorous vigilance against hazardous drug-drug and drug-disease contraindications.
Digoxin Toxicity: Molecular Mechanisms & Clinical Presentations
Digoxin is a cardiac glycoside that exerts positive inotropic and negative dromotropic effects through selective inhibition of the myocardial sarcolemmal Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase pump. At therapeutic levels, this inhibition increases intracellular sodium, which diminishes the trans-sarcolemmal sodium gradient and reduces calcium extrusion via the Na + / Ca 2 + \text{Na}^+/\text{Ca}^{2+} Na + / Ca 2 + exchanger (NCX). The resulting accumulation of intracellular calcium within the sarcoplasmic reticulum augments myocardial contractility while concurrently increasing vagal parasympathetic tone at the sinoatrial (SA) and atrioventricular (AV) nodes.
In toxic states, excessive intracellular calcium accumulation triggers delayed afterdepolarizations (DADs), producing triggered automaticity, severe ectopy, and life-threatening ventricular tachyarrhythmias. Concurrently, excessive vagal stimulation and direct nodal inhibition precipitate profound conduction block.
Acute vs. Chronic Digoxin Toxicity
The clinical presentation, laboratory abnormalities, and prognostic markers differ markedly between acute overdose and chronic accumulation:
Clinical Parameter Acute Digoxin Toxicity Chronic Digoxin Toxicity
Patient Profile Healthy individual or non-tolerant patient with acute intentional ingestion Elderly patient on long-term therapy with progressive renal failure or dehydration
Precipitating Factors Acute single ingestion of tablets or cardiac glycoside plants (foxglove, oleander) Acute kidney injury, hypokalemia, hypomagnesemia, or P-glycoprotein drug interactions
Gastrointestinal Symptoms Prominent: severe nausea, protracted vomiting, abdominal pain, diarrhea Mild or insidious: anorexia, vague nausea, weight loss, generalized weakness
Neurologic & Visual Signs Lethargy, dizziness, acute confusion Xanthopsia (yellow-green visual halos), photophobia, scotomas, delirium, hallucinations
Serum Potassium Level Marked Hyperkalemia ( > 5.0 mEq/L >5.0\text{ mEq/L} > 5.0 mEq/L ); reflects systemic Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase blockade Normal or Hypokalemic ; hypokalemia and hypomagnesemia potentiate toxicity at low levels
Serum Digoxin Concentration Extremely elevated ( > 10 to 15 ng/mL >10\text{ to }15\text{ ng/mL} > 10 to 15 ng/mL early post-ingestion) Moderately elevated ( 1.5 to 4.0 ng/mL 1.5\text{ to }4.0\text{ ng/mL} 1.5 to 4.0 ng/mL ) or occasionally "therapeutic" with severe symptoms
Primary Prognostic Factor Serum Potassium Concentration predicted mortality before Fab therapy existed (Bismuth 1973: about 50% at K + K^+ K + 5.0–5.5 mEq/L and nearly 100% above 5.5 mEq/L) Underlying cardiac substrate, degree of renal impairment, and electrolyte derangements
Important
In acute digoxin overdose, hyperkalemia is an extracellular shift resulting from widespread systemic blockade of Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase pumps in skeletal muscle and myocardium. The serum potassium concentration serves as a direct surrogate for the fraction of poisoned pumps and is the single strongest prognostic indicator of mortality.
Digitalis-Induced Dysrhythmias
Digoxin toxicity can provoke virtually any cardiac rhythm disturbance. The hallmark pathophysiologic combination is increased automaticity coupled with impaired AV conduction :
Ventricular Ectopy & Dysrhythmias : Frequent premature ventricular contractions (PVCs), often presenting as ventricular bigeminy or trigeminy; bidirectional ventricular tachycardia (alternating frontal plane QRS axis from beat to beat), which is virtually pathognomonic for digitalis poisoning; polymorphic or monomorphic ventricular tachycardia; ventricular fibrillation.
Conduction Delays & Bradyarrhythmias : Severe sinus bradycardia, sinus arrest, first-degree AV block, high-grade second-degree AV block (Mobitz I or II), and complete (third-degree) heart block.
Supraventricular Dysrhythmias : Paroxysmal atrial tachycardia (PAT) with 2:1 block (classic digitalis dysrhythmia; increased atrial automaticity with AV nodal conduction delay); slow atrial fibrillation with an unnaturally regular ventricular response (junctional escape rhythm indicating complete heart block).
Warning
Avoid direct current electrical cardioversion in patients with suspected severe digitalis toxicity if possible. Electrical shock in the setting of digoxin-induced intracellular calcium overload can trigger refractory, fatal ventricular fibrillation or asystole. If electrical cardioversion is mandatory for hemodynamic collapse, select the lowest possible initial energy setting (e.g., 25 to 50 Joules) and administer DigiFab emergently.
Digoxin-Specific Antibody Fragments (DigiFab)
Digoxin-specific Fab fragments (DigiFab, ovine) consist of sterile, purified, lyophilized monovalent Fab immunoglobulin fragments derived from sheep immunized with a digoxin-albumin conjugate. Papain enzymatic cleavage removes the Fc constant region, preventing complement activation, reducing immunogenicity, and facilitating rapid renal elimination.
Mechanism of Action
Each vial of DigiFab (40 mg) contains purified Fab fragments with a molecular weight of approximately 46,000 Daltons. Monovalent Fab fragments bind free intravascular digoxin with an affinity constant ( K a ≈ 10 9 to 10 10 M − 1 K_a \approx 10^9\text{ to }10^{10}\text{ M}^{-1} K a ≈ 1 0 9 to 1 0 10 M − 1 ) that is significantly higher than the affinity of digoxin for Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase . Once bound, the Fab-digoxin complex is pharmacologically inert and cleared renally via glomerular filtration (elimination half-life ~15 to 20 hours in normal renal function).
Clinical Indications for DigiFab
Cardiac arrest secondary to digitalis toxicity or life-threatening ventricular dysrhythmias (bidirectional VT, VT, VF).
Hemodynamically unstable bradyarrhythmias refractory to atropine (severe sinus bradycardia, second-degree or third-degree AV block).
Serum potassium > 5.0 mEq/L >5.0\text{ mEq/L} > 5.0 mEq/L in acute digitalis poisoning (independent of serum digoxin level or rhythm).
Ingestion of > 10 mg >10\text{ mg} > 10 mg of digoxin in healthy adults ( > 4 mg >4\text{ mg} > 4 mg or > 0.1 mg/kg >0.1\text{ mg/kg} > 0.1 mg/kg in children).
Steady-state serum digoxin concentration > 10 to 15 ng/mL >10\text{ to }15\text{ ng/mL} > 10 to 15 ng/mL in acute poisoning or > 2.0 to 3.0 ng/mL >2.0\text{ to }3.0\text{ ng/mL} > 2.0 to 3.0 ng/mL in chronic accumulation accompanied by progressive end-organ toxicity.
DigiFab Dosing Calculations & Formulas
Each 40 mg vial of DigiFab binds approximately 0.5 mg (500 mcg) of digoxin (or digitoxin).
Loading diagram...
1. Calculation Based on Steady-State Serum Digoxin Concentration
When a steady-state serum concentration (drawn at least 6 to 8 hours post-dose to allow complete tissue distribution) is known:
Number of Vials = Serum Digoxin (ng/mL) × Patient Weight (kg) 100 \text{Number of Vials} = \frac{\text{Serum Digoxin (ng/mL)} \times \text{Patient Weight (kg)}}{100} Number of Vials = 100 Serum Digoxin (ng/mL) × Patient Weight (kg)
Worked Clinical Example : A 70-kg patient with chronic toxicity presents with AV dissociation and a steady-state serum digoxin level of 8.0 ng/mL:
Number of Vials = 8.0 ng/mL × 70 kg 100 = 560 100 = 5.6 ≈ 6 vials \text{Number of Vials} = \frac{8.0\text{ ng/mL} \times 70\text{ kg}}{100} = \frac{560}{100} = 5.6 \approx 6\text{ vials} Number of Vials = 100 8.0 ng/mL × 70 kg = 100 560 = 5.6 ≈ 6 vials
2. Calculation Based on Known Ingested Amount
When the ingested amount of digoxin is known, assuming 80% systemic bioavailability for oral tablets:
Total Body Burden (mg) = Dose Ingested (mg) × 0.80 \text{Total Body Burden (mg)} = \text{Dose Ingested (mg)} \times 0.80 Total Body Burden (mg) = Dose Ingested (mg) × 0.80 Number of Vials = Total Body Burden (mg) 0.5 mg bound per vial \text{Number of Vials} = \frac{\text{Total Body Burden (mg)}}{0.5\text{ mg bound per vial}} Number of Vials = 0.5 mg bound per vial Total Body Burden (mg)
Worked Clinical Example : A patient ingests 20 tablets of 0.25 mg digoxin (5 mg total):
Body Burden = 5.0 mg × 0.80 = 4.0 mg \text{Body Burden} = 5.0\text{ mg} \times 0.80 = 4.0\text{ mg} Body Burden = 5.0 mg × 0.80 = 4.0 mg Number of Vials = 4.0 mg 0.5 mg/vial = 8 vials \text{Number of Vials} = \frac{4.0\text{ mg}}{0.5\text{ mg/vial}} = 8\text{ vials} Number of Vials = 0.5 mg/vial 4.0 mg = 8 vials
3. Empiric Dosing Protocols (When Levels and Amounts Are Unknown)
Acute Overdose with Instability / Cardiac Arrest : Administer 10 to 20 vials IV . In cardiac arrest, administer by rapid IV push. Twenty vials binds 10 mg of digoxin, which neutralizes a massive, lethal overdose.
Chronic Ingestion with Life-Threatening Toxicity : Administer 3 to 6 vials IV (infused over 30 minutes in stable patients). In chronic toxicity, total body distribution is vast, and smaller initial doses (1 to 2 vials) often reverse toxicity without precipitating sudden rebound heart failure or hypokalemia.
Post-DigiFab Monitoring & Critical Pitfalls
Total Digoxin Assays Are Uninterpretable : Commercial clinical laboratory digoxin immunoassays cannot distinguish between pharmacologically active free digoxin and inactive Fab-bound digoxin complexes. Following DigiFab administration, measured total serum digoxin concentrations will falsely surge to >10-fold baseline and remain elevated for 1 to 2 weeks (or longer in renal failure). Clinicians must follow clinical status, heart rate, and 12-lead ECG, NOT repeat total serum levels.
Hypokalemia : As DigiFab strips digoxin from myocardial and skeletal muscle Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase pumps, cellular potassium re-uptake occurs rapidly. Monitor serum potassium every 1 to 2 hours initially; treat hypokalemia aggressively to prevent secondary dysrhythmias.
Decompensation of Underlying Heart Failure or Rapid Atrial Fibrillation : Rapid neutralization of digoxin abruptly removes inotropic support and eliminates AV nodal brake, potentially precipitating pulmonary edema or rapid ventricular response.
Tricyclic Antidepressant (TCA) Toxicity
Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, doxepin, clomipramine) are among the most lethal prescription ingestions. Life-threatening toxicity stems from simultaneous antagonism across four critical receptor systems:
Myocardial Fast Sodium Channel Blockade (Phase 0 I Na \text{I}_{\text{Na}} I Na ) : Class IA antiarrhythmic effect. Slows depolarization, widens the QRS complex, prolongs the PR and QTc intervals, and induces terminal rightward axis deviation.
Peripheral Alpha-1 Adrenergic Blockade : Induces refractory peripheral vasodilation and severe distributive shock.
Central and Peripheral Muscarinic ( M 1 , M 2 M_1, M_2 M 1 , M 2 ) Blockade : Triggers the anticholinergic toxidrome (sinus tachycardia, mydriasis, hyperthermia, dry skin, delirium, urinary retention, bowel hypomotility).
Central GABA A \text{GABA}_{\text{A}} GABA A Receptor Antagonism : Provokes intractable central nervous system excitation, seizures, and status epilepticus. ELECTROCARDIOGRAPHIC PREDICTORS IN TCA OVERDOSE
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ QRS Duration < 100 ms: Low risk of seizures or dysrhythmias │
- │ QRS Duration > 100 ms: ~34% Risk of Seizures │
- │ QRS Duration > 160 ms: ~50% Risk of Life-Threatening Ventricular Dysrhythmias│
- │ Terminal Rightward Axis (Lead aVR): R wave > 3 mm OR R/S ratio > 0.7 │
- └─────────────────────────────────────────────────────────────────────────────┘
- Electrocardiographic Risk Stratification
QRS > 100 ms >100\text{ ms} > 100 ms : Strongly predicts impending generalized seizures (34% risk). Mandates immediate intravenous sodium bicarbonate therapy.
QRS > 160 ms >160\text{ ms} > 160 ms : Strongly predicts impending life-threatening ventricular dysrhythmias (monomorphic/polymorphic VT, ventricular fibrillation; 50% risk).
Terminal 40-ms Rightward Frontal Axis Shift in Lead aVR : Selective blockade of the right bundle branch results in a prominent terminal R wave > 3 mm R\text{ wave} > 3\text{ mm} R wave > 3 mm in lead aVR, or an R / S ratio > 0.7 R/S\text{ ratio} > 0.7 R / S ratio > 0.7 in aVR. This sign is highly sensitive for sodium channel blocker toxicity.
Sodium Bicarbonate Therapy: Protocols & Dual Molecular Mechanisms
Sodium bicarbonate (8.4% hypertonic solution, 1 mEq/mL; 50 mEq per 50 mL ampule) is the definitive, life-saving antidote for TCA cardiotoxicity.
Initial Resuscitation Bolus : 1 to 2 mEq/kg IV push (typically 1 to 2 ampules [50 to 100 mEq] administered over 1 to 2 minutes).
Repeat Titration : Repeat the 1 to 2 mEq/kg bolus every 3 to 5 minutes until the QRS complex narrows to < 100 ms <100\text{ ms} < 100 ms and systemic arterial hypotension improves.
Continuous Maintenance Infusion : Once initial QRS narrowing is achieved, initiate a continuous IV infusion mixed as 150 mEq sodium bicarbonate (3 ampules) in 1,000 mL of 5% Dextrose in Water ( D 5 W \text{D}_5\text{W} D 5 W ) (yielding a nearly isotonic solution of ~300 mOsm/L). Infuse at 150 to 250 mL/h (2 to 3 times the maintenance fluid rate).
Therapeutic Targets & Discontinuation Rules : Target a systemic arterial pH of 7.45 to 7.55 and serum sodium of 150 to 155 mEq/L. Stop or titrate down the infusion if arterial pH exceeds 7.55 or serum sodium exceeds 155 mEq/L to prevent severe metabolic alkalosis, hypokalemic tetany, and hypernatremia.
The Dual Mechanism of Action
Hypertonic Sodium Load : Infusing hypertonic sodium increases extracellular sodium concentration, steepening the electrochemical concentration gradient across the myocardial cell membrane. This passive electrochemical force overcomes the competitive drug blockade at the voltage-gated fast sodium channels.
Serum Alkalinization (pH 7.45–7.55) : TCAs are weak bases with a p K a \text{p}K_a p K a between 8.5 and 9.5. Elevating extracellular pH shifts the chemical equilibrium toward the non-ionized (uncharged, neutral) lipophilic state. The non-ionized TCA has a dramatically lower binding affinity for the neutral open/inactivated conformation of myocardial sodium channels, accelerating dissociation of the drug from the receptor.
Tip
Hypertonic 3% sodium chloride (100 to 250 mL IV bolus) can be utilized if the arterial pH reaches 7.55 but the QRS remains widened > 100 ms >100\text{ ms} > 100 ms , providing an additional sodium load without further alkalinization.
Refractory TCA Cardiotoxicity Management
Refractory Hypotension : First-line vasopressor is norepinephrine (direct alpha-1 agonist that overcomes competitive blockade and restores systemic vascular resistance). Avoid indirect-acting agents like dopamine, which depend on depleted endogenous catecholamine stores.
Antiarrhythmic Drug Selection : Class IA (procainamide, quinidine), Class IC (flecainide, propafenone), and Class III (amiodarone, sotalol) antiarrhythmics are STRICTLY CONTRAINDICATED . Class IA and IC agents exacerbate sodium channel blockade, while Class III agents worsen QTc prolongation and precipitate torsades de pointes. If a ventricular dysrhythmia is refractory to sodium bicarbonate, lidocaine (Class IB, 1 to 1.5 mg/kg IV push) is the only safe antiarrhythmic because of its rapid channel on-off binding kinetics.
Rescue Therapy : In refractory arrest or shock, administer Intravenous Lipid Emulsion (ILE 20%) : 1.5 mL/kg IV bolus over 2 to 3 minutes, followed by 0.25 mL/kg/min infusion. Consider emergent venoarterial extracorporeal membrane oxygenation (VA-ECMO).
Anticholinergic Toxidrome & Physostigmine
The anticholinergic (antimuscarinic) toxidrome results from competitive antagonism of acetylcholine at central and peripheral muscarinic ( M 1 – M 5 M_1\text{--}M_5 M 1 – M 5 ) receptors. Common causative agents include first-generation antihistamines (diphenhydramine, hydroxyzine), antiparkinsonian agents (trihexyphenidyl, benztropine), antispasmodics (oxybutynin, dicyclomine), belladonna alkaloids (atropine, scopolamine), and toxic plants ( Datura stramonium [jimsonweed], Atropa belladonna ).
Clinical Manifestations
"Blind as a bat" : Pupillary mydriasis with loss of accommodation and cycloplegia; blurred vision.
"Dry as a bone" : Complete anhidrosis, parched oral mucous membranes, dry axillae.
"Red as a beet" : Cutaneous vasodilation and flushing, predominantly over the face and upper torso.
"Hot as a hare" : Hyperthermia, driven by loss of evaporative diaphoresis and central thermoregulatory resetting.
"Mad as a hatter" : Anticholinergic delirium, agitation, visual and auditory hallucinations, mumbling speech, "phantom picking" (carphologia), and fluctuating stupor.
"Full as a flask" : Acute urinary retention and severe bladder distension; hypoactive or absent bowel sounds.
Sinus Tachycardia : The earliest, most sensitive, and most consistent physiological marker of muscarinic blockade.
Physostigmine Salicylate: Pharmacology & Dosing
Physostigmine is a naturally occurring tertiary amine alkaloid extracted from the Calabar bean ( Physostigma venenosum ).
Mechanism : Reversibly carbamylates and inhibits acetylcholinesterase, preventing the breakdown of acetylcholine. Unlike quaternary amine inhibitors (neostigmine, pyridostigmine, edrophonium), physostigmine readily crosses the blood-brain barrier because its tertiary amine structure is lipophilic, effectively reversing both central delirium and peripheral muscarinic signs.
Dosing & Administration : 0.5 to 2.0 mg IV (pediatrics: 0.02 mg/kg, maximum single dose 0.5 mg) administered as a slow IV infusion over at least 5 minutes . Rapid push can induce severe bradycardia, hypersalivation, and seizures. If clinical response is partial, the dose may be repeated after 10 to 15 minutes.
Bedside Safety Requirement : Atropine (1 to 2 mg IV) must be immediately drawn up and present at the bedside before administering physostigmine to treat any iatrogenic cholinergic crisis (bradycardia, severe bronchorrhea).
Strict Contraindications to Physostigmine
Known or Suspected Tricyclic Antidepressant Overdose : Historically, administering physostigmine in TCA overdoses caused sudden, intractable complete heart block, asystole, and fatal cardiac arrest. TCAs already impair cardiac conduction; sudden cholinergic surge further depresses SA and AV nodal pacemakers.
Electrocardiographic Conduction Delays : Any patient with QRS prolongation ( > 100 ms >100\text{ ms} > 100 ms ) , PR prolongation , second- or third-degree AV block, or intraventricular conduction defects.
Severe Reactive Airway Disease : Asthma or severe COPD (cholinergic bronchospasm and hypersecretion).
Mechanical Obstruction : Intestinal or urinary bladder mechanical obstruction.
Toxicology Reference Matrix: Antidotes & Protocols
Clinical Entity Primary Toxic Mechanism Diagnostic Hallmarks First-Line Antidote / Rescue Drug Standard Administration Protocol Critical Pitfalls & Red Lines
Digoxin Toxicity Sarcolemmal Na + / K + -ATPase \text{Na}^+/\text{K}^+\text{-ATPase} Na + / K + -ATPase pump inhibition PVCs, bidirectional VT, high-grade AV block, PAT with block; hyperkalemia in acute DigiFab (Digoxin-specific Fab fragments) Vials = (Digoxin ng/mL * Weight kg) / 100 ; Empiric 10–20 vials (acute) or 3–6 vials (chronic) Total serum digoxin assays falsely skyrocket; avoid electrical cardioversion; watch for hypokalemia.
TCA Overdose Myocardial fast sodium channel ( I Na \text{I}_{\text{Na}} I Na ) & alpha-1 blockade QRS > 100 ms >100\text{ ms} > 100 ms (seizures), QRS > 160 ms >160\text{ ms} > 160 ms (VT/VF), terminal R in aVR > 3 mm >3\text{ mm} > 3 mm Sodium Bicarbonate 8.4% 1–2 mEq/kg IV bolus q3–5min , then continuous infusion (150 mEq in 1 L D 5 W \text{D}_5\text{W} D 5 W ) targeting pH 7.45–7.55 Class IA/IC/III antiarrhythmics strictly contraindicated; stop bicarbonate if pH > 7.55 >7.55 > 7.55 or Na > 155 >155 > 155 .
Anticholinergic Delirium Central & peripheral muscarinic receptor antagonism Mydriasis, dry flushed skin, hyperthermia, urinary retention, agitated delirium Physostigmine Salicylate 0.5–2.0 mg slow IV over at least 5 minutes ; repeat once in 10–15 min PRN Strictly contraindicated in TCA ingestion, widened QRS, PR prolongation, and asthma; keep atropine bedside.